EE209 Non-Invasive Tests (NITs) to Risk-Stratify Patients with Noncirrhotic Metabolic-Associated Steatohepatitis (MASH) in a Specialty Setting Eligible for Resmetirom: A Cost-Effectiveness Analysis from a U.S. Payer Perspective
Abstract
Authors
John O'Donnell Yestle Kim Melissa Gomez Montero Mehdi Javanbakht Suneil Hosmane Amir Ansaripour